SAR131675: Selective ATP-Competitive VEGFR-3 Inhibitor for Advanced Tumor and Fibrosis Research

Principle and Setup: Precision Targeting of the VEGFR-3 Pathway

SAR131675 (SKU: B2301), available from APExBIO, is a next-generation, highly selective ATP-competitive VEGFR-3 inhibitor designed to advance the study of lymphangiogenesis, angiogenesis, and their roles in cancer and fibrotic diseases. With an IC₅₀ of 23 nM and K_i of 12 nM against recombinant human VEGFR-3 kinase, SAR131675 has demonstrated exceptional potency for inhibiting VEGFR-3 autophosphorylation in cellular contexts (HEK cells: IC₅₀ 30–50 nM). Selectivity is a hallmark: SAR131675 shows minimal inhibition of VEGFR-1 (IC₅₀ >3 μM), moderate inhibition of VEGFR-2 (IC₅₀ 235 nM), and negligible off-target activity across a broad panel of 65 kinases, 107 non-kinase enzymes/receptors, and 21 ion channels. This makes it an ideal VEGFR-3 selective kinase inhibitor for discerning VEGFR signaling pathway mechanisms and isolating VEGFC/VEGFD-mediated effects in the lymphangiogenesis and angiogenesis pathways.

Key properties include:

• High selectivity—no significant activity against non-VEGFR kinases, enzymes, or ion channels
• Potent inhibition of VEGFC- and VEGFD-induced lymphatic endothelial cell survival (IC₅₀: 14 nM and 17 nM)
• Effective suppression of endothelial cell migration induced by VEGFA (<100 nM) and VEGFC (<30 nM)
• Demonstrated tumor volume reduction and anti-lymphangiogenic effects in preclinical mouse models

This profile positions SAR131675 as a benchmark anti-lymphangiogenic agent, anti-angiogenic compound, and preclinical tool for evaluating tumor angiogenesis pathway blockade, cancer biology, and fibrotic disease progression.

Step-by-Step Workflow: Integrating SAR131675 into Experimental Protocols

1. Compound Handling and Preparation

SAR131675 is supplied as a solid, cell-permeable compound. It is insoluble in DMSO, ethanol, or water, so researchers should dissolve it using the recommended protocol (typically with a small amount of acidified solvent or compatible vehicle) immediately prior to use. Solutions are not recommended for long-term storage—freshly prepare before each experiment and store the solid at -20°C for optimal stability.

2. In Vitro Assays

• Kinase Activity: For VEGFR-3 kinase inhibition assays, titrate SAR131675 from 1 nM to 1 μM to accurately determine dose-response and IC₅₀ values. Confirm selectivity by parallel assays with VEGFR-1 and VEGFR-2.
• Cellular Phosphorylation: In HEK or relevant endothelial cells, treat with SAR131675 (10–100 nM range) for 1–2 hours prior to VEGFC/VEGFD stimulation. Immunoblot for phosphorylated VEGFR-3 to confirm inhibition.
• Lymphatic Endothelial Cell Survival/Migration: Employ CCK-8 or similar viability assays after VEGFC/VEGFD stimulation. For migration, use transwell or wound healing assays, adding SAR131675 to the medium at 10–100 nM.

3. In Vivo Applications

• Tumor Models: For murine tumor xenografts (e.g., 4T1 mammary carcinoma), administer SAR131675 at 30 mg/kg/day by oral gavage or as specified in your protocol. Monitor tumor volume, lymphangiogenesis (LYVE-1, podoplanin staining), and angiogenesis (CD31 staining).
• Fibrosis Models: In hepatic fibrosis or NASH models induced by high-fat diet, co-administer SAR131675 from week 9 onward (e.g., 30 mg/kg/day for 16 weeks) as in the reference study. Assess fibrosis markers (COL1A1, ACTA2), macrophage infiltration (Ly6C^high), and VEGFC/VEGFR-3 signaling.

4. Data Analysis and Controls

Include negative controls (vehicle only), positive controls (VEGFR-3 genetic knockdown/knockout), and off-target controls (VEGFR-1/2 inhibition) to confirm SAR131675’s selective activity. Quantify IC₅₀ values, percent inhibition, and pathway-specific readouts.

Advanced Applications and Comparative Advantages

SAR131675 is a research-enabling compound for dissecting the VEGFR signaling pathway in cancer, fibrosis, and metastasis models. Key differentiators include:

• Dissecting Lymphangiogenesis vs. Angiogenesis: Its remarkable selectivity allows researchers to pinpoint the contributions of VEGFR-3–mediated lymphangiogenesis (metastatic niche formation, immune cell trafficking) separately from VEGFR-2–driven angiogenesis.
• Preclinical Validation: In a landmark study on NASH-associated fibrosis, SAR131675 significantly reduced hepatic fibrosis, downregulated VEGFC and CCL2/CCR2, and altered macrophage phenotypes, mirroring the effects of hepatocyte-specific Vegfc knockout. These results highlight its power as a VEGFR-3 autophosphorylation inhibitor and a tool for probing the tumor microenvironment and immune regulation.
• Minimal Off-Target Activity: Extensive profiling against >60 kinases, >100 non-kinase enzymes/receptors, and 21 ion channels showed negligible off-target effects, supporting its use for mechanistic studies where pathway specificity is critical.
• Translational Relevance: The compound’s anti-lymphangiogenic and anti-angiogenic actions have been validated in vivo, with robust tumor volume reduction and suppression of lymphatic vessel formation—see this article for a mechanistic perspective, and this resource for insights on metastasis and fibrosis research.
• Complementary to Genetic Models: SAR131675 enables rapid, reversible VEGFR-3 inhibition, making it ideal for confirming or extending findings from conditional knockout models or RNAi-based studies.

For a comparative breakdown with other selective kinase inhibitors and protocol-driven guidance, see "Enhancing Lymphangiogenesis and Angiogenesis Research with SAR131675", which complements this workflow-focused approach by addressing real-world challenges and reproducibility in VEGFR pathway studies.

Troubleshooting and Optimization Tips

• Solubility Issues: SAR131675 is insoluble in DMSO, ethanol, and water. Always use the recommended acidified or specialized solvent system, freshly prepared. Avoid long-term storage of solutions; keep solid at -20°C.
• Batch Consistency: Source SAR131675 from reputable suppliers like APExBIO to ensure batch-to-batch reproducibility and purity, which is critical for IC₅₀ accuracy and reproducibility in sensitive assays.
• Concentration Titration: Perform a broad concentration range (e.g., 1–500 nM) in pilot assays to determine the optimal working concentration for your cell type and endpoint. Exceeding 100 nM may increase the risk of off-target effects in some systems.
• Vehicle Controls: Use vehicle-only controls in all experiments to account for potential solvent effects, especially in cell viability and migration assays.
• Pathway Validation: Confirm pathway inhibition by immunoblotting for phosphorylated VEGFR-3 and downstream effectors; include parallel assays for VEGFR-1/2 to validate selectivity.
• Metabolic Effects: While SAR131675 is a powerful preclinical research tool, note that its development as a drug candidate was discontinued due to adverse metabolic effects in animal models. When using in vivo, closely monitor metabolic parameters and limit duration as appropriate.

Future Outlook: Harnessing SAR131675 in Translational Research

Despite its discontinuation as a therapeutic candidate, SAR131675 remains a cornerstone research compound for interrogating the VEGFR signaling pathway, lymphangiogenesis, and the tumor microenvironment. It is particularly impactful in:

• Expanding Cancer Biology Understanding: As a tumor growth inhibition agent and tumor volume reduction tool, SAR131675 facilitates deeper exploration of metastasis mechanisms, immune cell migration, and resistance pathways in oncology.
• Fibrosis and Chronic Disease Models: The reference study underscores its value in hepatic fibrosis and NASH models, offering a path to dissect the interplay between VEGFC/VEGFR-3 and immune regulation.
• Preclinical Platform Development: With its unique selectivity and minimal off-target profile, SAR131675 is poised to support the next generation of preclinical assays and high-content screening platforms for drug discovery in the VEGFR-3 axis.
• Synergy with Systems Biology: Coupling SAR131675 with transcriptomic and proteomic profiling (e.g., GEO datasets) can uncover new nodes of regulation within the lymphangiogenesis and angiogenesis pathways.

For those seeking a robust, reproducible, and highly selective ATP-competitive VEGFR-3 inhibitor for lymphangiogenesis research, angiogenesis studies, or tumor metastasis research, SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor from APExBIO delivers proven performance and clarity in mechanistic studies.

Conclusion

SAR131675 sets the gold standard for selective VEGFR-3 kinase inhibition in cancer and fibrotic disease research. Its unique selectivity, quantifiable potency, and reproducibility across in vitro and in vivo models position it as an invaluable tool for dissecting the VEGFR signaling pathway, evaluating anti-angiogenic and anti-lymphangiogenic strategies, and supporting translational breakthroughs. For detailed protocols, real-world troubleshooting, and advanced applications, researchers are encouraged to explore both the original reference study and the suite of complementary articles linked above. By leveraging the precision of SAR131675, scientists can confidently advance the frontiers of cancer biology, fibrosis, and vascular signaling research.